EGRX FINANCIAL STATEMENTS

Eagle Pharmaceuticals Inc — balance sheet, income statement and cash flow trends

EGRXEagle Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q2 2023 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue257.6 M $-5.4%

Gross Profit179.9 M $-10.2%

Operating Income23.7 M $-59.0%

EBITDA57 M $+6.2%

Net Income15.6 M $-31.7%

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
EGRX	-5.4%	69.8%	22.1%	6.0%
TRILC	32.0%	33.8%	28.5%	-2.2%
HIK	7.4%	41.4%	20.0%	12.0%
DEVA	7.7%	32.5%	12.0%	-4.4%
TLRY	3.8%	27.7%	-156.2%	-158.8%
HLN	-26.7%	61.5%	25.2%	12.6%
Industry median	7.5%	60.6%	18.2%	4.0%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q2 2023

Equity252 M $62%
Current Liabilities86.6 M $21%
Long-term Liabilities66.2 M $16%

Key Figures

YoY change

Total Assets404.8 M $+6.0%

Total Liabilities152.8 M $+6.3%

Total Equity252 M $+5.9%

Cash & ST Investments15.4 M $-58.0%

Total Debt71.6 M $+33.6%

Net Debt56.3 M $+230.3%

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
EGRX	2.16	28.4%	0.99	62.3%
TRILC	0.99	207.6%	2.71	23.5%
HIK	1.82	61.8%	1.87	45.7%
DEVA	2.00	23.1%	0.89	69.9%
TLRY	2.79	20.4%	-0.07	75.1%
HLN	0.92	52.3%	3.50	50.3%
Industry median	2.22	46.3%	1.24	45.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q2 2023 · TTM

Key Figures

YoY change

Operating Cash Flow-9.3 M $-126.2%

Capital Expenditures84 K $-62.2%

Free Cash Flow-9.4 M $-126.6%

Dividends Paid247 K $-86.6%

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
EGRX	-3.6%	-3.6%	0.0%	-59.9%
TRILC	10.9%	-0.3%	11.2%	-505.5%
HIK	11.6%	5.8%	5.8%	96.8%
DEVA	25.8%	19.3%	12.8%	-590.3%
TLRY	-5.6%	-8.3%	3.8%	3.5%
HLN	12.5%	11.3%	1.2%	99.0%
Industry median	15.2%	11.6%	2.5%	84.3%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on EGRX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jun 26, 26. This content is for informational purposes only and is not investment advice.